# US 2004/0063187 A1 · Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0063187 A1
- Document ID: US20040063187A1
- Status: Published application
- Kind: A1
- Application number: 10/674,408
- Filed: 2003-10-01
- Published: 2004-04-01
- Earliest claimed: 1999-08-06
- Assignees: Aventis Behring GmbH
- Inventors: Juergen Roemisch; Annette Feussner; Hans-Arnold Stoehr
- Web page: https://patentgrep.com/patent/US20040063187A1

## CPC

- B01D 15/3804: {Affinity chromatography}
- B01D 15/3828: {Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- B01D 15/1871: {placed in series}
- B01D 15/327: {with hydrophobic interaction}
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme by use of one or more affinity chromatography separation processes and/or fractional precipitation is described, in which the affinity chromatography separation process used is adsorption on calcium phosphate/hydroxyapatite, a hydrophobic matrix, a chelate matrix, a matrix on which heparin or a substance related to heparin, such as heparan sulfate or dextran sulfate, is immobilized, and/or a matrix which is coated with an immobilized monoclonal or polyclonal antibody directed against the protein to be isolated, or its F(ab) or F(ab)2 fragments. A pharmaceutical preparation and a reagent are moreover described which contain the said protease and its proenzyme.

## Claims

### Claim 1

A process for the preparation in pure form of the protease activating blood clotting factor VII and/or its proenzyme by use of one or more affinity chromatography separation processes and/or fractional precipitation, which comprises using, as the affinity chromatography separation process, adsorption on
calcium phosphate/hydroxyapatite,
a hydrophobic matrix,
a chelate matrix,
a matrix on which heparin or a substance related to heparin, such as heparan sulfate or dextran sulfate, is immobilized, and/or
a matrix which is coated with an immobilized monoclonal or polyclonal antibody directed against the protein to be isolated, or its F(ab) or F(ab)2 fragments.

### Claim 2 (depends on 1)

The process as claimed in claim 1, wherein one of the chromatographic separation processes or fractional precipitation on its own or each of the abovementioned processes is used in any desired combination with another of the chromatographic separation processes mentioned in claim 1.

### Claim 3 (depends on 1)

The process as claimed in claim 1, which is carried out in the presence of one or more protein stabilizers which are selected from the groups consisting of
complexing agents of divalent ions, preferably EDTA, EGTA or citrate, and/or
divalent ions, preferably calcium ions, and/or
amino acids, preferably glutamate, arginine, lysine or glycine, and/or
sugars, preferably glucose, arabinose, mannose or mannitol, and/or
solubilizers, preferably hydroxyproline, and/or
detergents, preferably Tween® or Triton®, and/or
alcohols, preferably ethylene glycol or polyethylene glycol, and/or
proteins, preferably albumin, gelatin, fibronectin, vitronectin or similar proteins, and/or
reductants, preferably dithiothreitol, mercaptoethanol or cysteine, and/or
proteinase inhibitors such as aprotinin, α-2-antiplasmin, C1-esterase inhibitor, the inter-α-trypsin inhibitor, the antithrombin III/heparin inhibitor or synthetic inhibitors.

### Claim 4 (depends on 1)

The process as claimed in claim 1, wherein, for the affinity chromatography separation of the protease activating factor VII from its proenzyme by means of stepwise elution, a substance which has bonds of different strength to the protease on the one hand and to the proenzyme on the other hand is immobilized on the support material, the different eluates are then collected separately from one another and the respective protein is isolated from them.

### Claim 5 (depends on 1)

The process as claimed in claim 1, wherein the fractional precipitation of the protease and/or its proenzyme from its solution is carried out by addition of
polyethylene glycol from a concentration of at least 10% by weight or
ammonium sulfate from a concentration of at least 15% by weight.

### Claim 6 (depends on 3)

A pharmaceutical preparation, which comprises the protease activating blood clotting factor VII and/or its proenzyme together with one or more protein stabilizers as set forth in claim 3, for assisting blood clotting in the case of a tendency to bleeding, in the case of a lack of factors of the endogenous clotting pathway, as FEIBA or for the prophylaxis and/or therapy of syndromes associated with thrombotic complications, in inherited or acquired deficiency states of the protease or its proenzyme, for assisting wound healing alone or as a constituent of a fibrin adhesive, a web and in combination with growth factors for subcutaneous, intramuscular, intravenous or topical treatment.

### Claim 7 (depends on 6)

The use of a pharmaceutical preparation of claim 6 for the coating of surfaces of articles consisting of plastic or metals to be implanted in the body, such as synthetic heart valves, blood vessels or cannulas inserted for taking blood or for artificial feeding.

### Claim 8 (depends on 3)

A reagent comprising the protease activating blood clotting factor VII and/or its proenzyme together with one or more protein stabilizers as set forth in claim 3 for use in biological test systems and for antigen detection.
